Framingham – REGICOR
| Background info: Framingham-REGICOR |
|
1) End-points measured
- 10 year risk of “hard” CHD
2) Profile of original population at baseline
- Gerona, Spain
- Age: 25-74
- Baseline free of prevalent CHD
- Participant number: 1480 (709 men, 771 women)
- Population selected from: REGICOR population registry
3) Validation (the following prospective studies excludes cohort with history of CVD and diabetes at baseline)
| Author | Year | Ethnicity | Age group | Follow up | Calibration ^ | Discrimination ^^ | Conclusion |
|---|---|---|---|---|---|---|---|
| Buitrago (3) | 2006 | Spainish | 40-65 | 10 years | 0.62 (calculated) | SCORE obtains better validity | |
| Buitrago (4) | 2011 | Spanish | 35-74 | 10 years | 1.64 | 0.69 | Under-predict risk by 64% |
| Comin (5) | 2007 | Spanish | 35-74 | 5 years | positive predictive value | REGICOR gives the best balance of sensitivity and specificity | |
| Marrugat (6) | 2007 | Spanish | 35-74 | 5 years | 0.69 (men), 0.81 (women) | Predicted accurately and reliably compared to original (Framingham-ATPIII) which overestimates. | |
| Marrugat (7) | 2011 | Spanish | 35-74 | 7.1 years(mean) | Hosmer and Lemeshow goodness-of-fit test for each decile risk group performed | 0.78 (men), 0.82 (women) | The function accurately predicts coronary disease events at 10 years |
| Marrugat (8) | 2014 | Spanish | 35-74 | 9.3 years (mean) | C-statistic 73.1 (men), 78.1 (women) | Framingham-REGICOR overestimate risk |
Note:
|
4) Length of follow up
- 10 years
5) Risk factors involved
- Non-modifiable risk factors
- Age
- Modifiable risk factors
- Diabetes
- Smoking
- JNC-V blood pressure categories (JNC: Joint National Committee)
- NCEP total cholesterol categories (NCEP: National Cholesterol Education Programme)
- LDL cholesterol categoriess Framingham-Wilson
6) Limitations
- The incidence in Girona, Spain (where the REGICOR registry is conducted) has a acute myocardial infarction incidence 15% below the Spanish average (2).
References
Primary publication:
1. Marrugat J, D’Agostino R, Sullivan L, Elosua R, Wilson P, Ordovas J, et al. An adaptation of the Framingham coronary risk function to southern Europe Mediterranean areas. J Epidemiol Comm Health 2003; 57: 634-638 http://jech.bmj.com/content/57/8/634.full.pdf
2. Marrugat J, Solanas P, D’Agostino R, et al. Coronary risk estimation in Spain using a calibrated Framingham function. Rev Esp Cardiol. 2003;56(3):253-261. http://www.revespcardiol.org/sites/default/files/elsevier/pdf/255/255v56n03a13048453pdf001.pdf
3. Buitrago Ramirez F, Canon Barroso L, Diaz Herrera N, Cruces Muro E, Bravo Simon B, Perez Sanchez I. Comparison of the SCORE function chart and the Framingham-REGICOR equation to estimate the cardiovascular risk in an urban population after 10 years of follow-up. Medicina Clinica. 2006;127(10):368-373.
4. Buitrago F, Calvo-Hueros JI, Canon-Barroso L, et al. Original and REGICOR Framingham functions in a nondiabetic population of a Spanish health care center: a validation study. Annals of Family Medicine. 2011;9(5):431-438.
5. Comin E, Solanas P, Cabezas C, et al. Estimating cardiovascular risk in Spain using different algorithms. Revista Espanola de Cardiologia. 2007;60(7):693-702.
6. Marrugat J, Subirana I, Comin E, et al. Validity of an adaptation of the Framingham cardiovascular risk function: the VERIFICA Study. Journal of Epidemiology & Community Health. 2007;61(1):40-47.
7. Marrugat J, Vila J, Baena-Diez JM, et al. Relative validity of the 10-year cardiovascular risk estimate in a population cohort of the REGICOR study. Revista Española de Cardiología. 2011;64(5):385-394.
8. Marrugat J, Subirana I, Ramos R, et al. Derivation and validation of a set of 10-year cardiovascular risk predictive functions in Spain: The FRESCO Study. Preventive Medicine. 2014;61:66-74.